List of Field Safety Notices from 1 to 5 Deceber 2025.
Similar Posts
Policy paper: Rare therapies and UK regulatory considerations
A paper outlining MHRA’s intentions to make it quicker and easier to get rare disease therapies tested, manufactured and approved in the UK.
Transparency data: Medicines and Healthcare products Regulatory Agency spending over £25,000: 2024 to 2025
Information on Medicines and Healthcare products Regulatory Agency spending over £25,000.
MHRA Chair welcomes re-appointment of three non-executive directors
Professor Anthony Harnden has congratulated the trio of Agency board members on the extension of their appointments.
Class 2 Medicines Recall: Depo-Medrone 80 mg in 2 mL, Maxearn Limited EL(25)A/29
A batch of Depo-Medrone has been released to the market with an error. The vial over label incorrectly states that the total vial content is 40 mg in 1 mL, when the correct total vial content is 80mg in 2 mL (with a concentration of 40mg/ml of methylprednisolone acetate).
UK and Singapore launch a regulatory innovation corridor to speed up access to breakthrough health technologies
Patients in the UK and Singapore could gain faster access to cutting-edge healthcare innovations under a new partnership bringing two globally respected regulators together with one of the world’s leading biotech creators.
MHRA confirms taking paracetamol during pregnancy remains safe and there is no evidence it causes autism in children
Paracetamol should be taken as directed in the patient information leaflet